Coverage dated January 29, 2025 to January 31, 2025
FDA approves JournaVX, a non-opioid pain relief option for adults
Headline from WHEC Rochester
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in 25 years. Developed by Vertex Pharmaceuticals, JournaVX is designed to treat moderate to severe acute pain in adults.
WHEC Rochester's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain, while reducing the effects of the opioid crisis.
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
For veterans who’ve spent years toughing out chronic pain with little more than grit and Motrin, the approval of Journavx might be just the thing we've been waiting for—if it lives up to the hype.
The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction or overdose linked to drugs like Vicodin and OxyContin.
Suzetrigine (Journavx) is the first non-opioid pain medication to be approved in the US in 20 years. It could help over 80 million Americans living with severe acute pain and reduce the effects of the opioid crisis.
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals' Journavx for short-term pain...
The FDA approved the first new class of non-opioid painkillers in more than two decades, the agency said Thursday. Suzetrigine, branded as Journavx, works to block receptors before they reach the brain in patients with surgical or injury pain.
A new non-opioid painkiller, JournaVX, has received approval from the FDA, marking the first new type of pain medication in 25 years. Developed by Vertex Pharmaceuticals, JournaVX is designed to treat moderate to severe acute pain in adults.
